ReviewJournal of clinical medicine research2020
The Impact of Cannabidiol on Psychiatric and Medical Conditions.
Review in Journal of clinical medicine research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
- Sex differences in the disposition of cannabidiol and its metabolites in mice.Journal of cannabis research · 2026Article
- Cannabinoids and ADHD: a New Frontier in Neuropharmacology?Journal of molecular neuroscience : MN · 2025Review
- Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Understanding the Potential of CBD for Health Benefits: An Overview.Current drug discovery technologies · 2025Review
- CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated head and neck squamous cell carcinoma.Frontiers in immunology · 2025Article
- Understanding the online landscape of cannabis discourse: a Twitter analysis.Frontiers in public health · 2025Article
- P2X7 receptors from the perspective of NLRP3 inflammasome pathway in depression: Potential role of cannabidiol.Brain, behavior, & immunity - health · 2024Article
- The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder.Pain and therapy · 2024Review
- CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.Pharmaceutics · 2024Review
- CBD's potential impact on Parkinson's disease: An updated overview.Open medicine (Warsaw, Poland) · 2024Review
- Cannabis as a Source of Approved Drugs: A New Look at an Old Problem.Molecules (Basel, Switzerland) · 2023Review
- Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.Behavioural neurology · 2023Review
- Effects of Cannabidiol in Adolescent and Young Adult Depressive and Anxiety Disorders: A Systematic Review of Clinical and Preclinical Research.Adolescent psychiatry (Hilversum, Netherlands) · 2023Article
- Review
- CBD enhances the cognitive score of adolescent rats prenatally exposed to THC and fine-tunes relevant effectors of hippocampal plasticity.Frontiers in pharmacology · 2023Article
- Reducing Effect of Cannabidiol on Alcohol Self-Administration in Sardinian Alcohol-Preferring Rats.Cannabis and cannabinoid research · 2022Article
- Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders.Biomedicines · 2022Review
- Cannabinoids for Agitation in Alzheimer's Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical and psychiatric conditions: depression, anxiety, post-traumatic stress disorder, Alzheimer's or other cognitive illnesses as well as pain. There is also a new trend to use CBD for the treatment of opioid use disorder. The one CBD product on the market that is FDA approved for the treatment of childhood epilepsy forms Dravet and Lennox-Gastaut syndromes is available under the name Epidiolex. There is a significant difference between this medication and the over-the-counter CBD products that contain very inconsistent strengths of CBD, if they contain it at all, and vary in percentage even from sample to sample. Frequently the so-called CBD products are not containing any CBD at all, but mostly containing THC. This article is a systematic review of literature reviewing the available clinical data on CBD, for use in various medical and psychiatric conditions with focus on a review of the pharmacology and toxicity. Resources used were ORVID, PubMed, MEDLINE, PsychINFO, EMBASE with keywords CBD, cannabidiol, hemp and cannabinoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.